Stock AnalizAgios Pharmaceuticals, Inc. AGIO
Biotechnology: Pharmaceutical Preparations · IPO 2013 · data as of November 13, 2026
Agios Pharmaceuticals, Inc. (AGIO) is a healthcare company listed in the US with a market value of about $1.9B. In the twelve months to September 30, 2026 it had revenue of $141M and net income of -$373M, a net margin of -264.8%.
Its overall Stock Analiz score is 1.0 out of 5 (weak). The strongest part is future growth (3/5); the weakest is value (0/5).
Key numbers: a 5-year average ROIC of -32%.
Score: 1.0 / 5
Checks passed
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 10 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $141M | $54M | — | $27M | $14M | — | $0 | $118M | $94M | $43M | $70M |
| Net income | -$373M | -$413M | $674M | -$352M | -$232M | $1.6B | -$327M | -$411M | -$346M | -$315M | -$198M |
| Free cash flow | -$336M | -$377M | -$392M | -$297M | -$314M | -$413M | -$305M | -$383M | -$311M | -$290M | $29M |
| EPS (diluted) | $-6.32 | $-7.12 | $11.64 | $-6.33 | $-4.23 | $26.55 | $-4.74 | $-6.86 | $-6.03 | $-6.75 | $-5.07 |
| Net margin | -264.8% | -764.0% | — | -1312.6% | -1627.8% | — | — | -349.0% | -366.6% | -731.6% | -284.0% |
| ROIC | — | -38.2% | -25.0% | -44.3% | -32.8% | -21.5% | -52.6% | -42.0% | -52.7% | -85.4% | -56.0% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 9 analysts is $46.11, 46% above the current price; targets range from $32.00 to $74.00; the consensus rating is “Buy”; expected EPS is $-5.56 for the fiscal year ending December 31, 2026.
Frequently asked questions
Does Agios Pharmaceuticals pay a dividend?
Not currently.
Is Agios Pharmaceuticals a good stock to buy?
We do not give buy or sell advice. Agios Pharmaceuticals scores 1.0 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.